Market Analysis - Metabolic Syndrome 2017
Scope and Importance of Metabolic Syndrome:
Scope: The Scope of the conference is to gather all the Doctors, Researchers, Business Professionals and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere. This Metabolic Syndrome Conference is the premier event focusing on understanding individual and organizational behaviour and decision-making related to Diabetes and Endocrinology, biotechnology, pharmaceuticals, medicals and academia.
Importance: Conference on Metabolic Syndrome is a much celebrated conference which basically deals with the latest research and developments in the sphere of Diabetes and Endocrinology. This Conference will provide a perfect platform to all the International mix of leading Research Scholars, and Scientists achieved eminence in their field of study, research academicians from the universities and research institutions, industrial research professionals and business associates along with Ph.D. Students to come and inform all the attendees about the latest scientific advancements on the respective sphere.
Today’s Market Study of Metabolic Syndrome in USA | Europe | Middle East | Asia Pacific
USA: The quantity of Americans with metabolic disorder somewhere around 1999 and 2006 was most likely around 68 million. It has reported that among all young ladies between the ages of 20 and 39, 17% had metabolic disorder in 1999-2006, will reach 30% in 2025-2030.
Europe: About 8-18% of total adult healthcare expenditure in the Europe is metabolic syndrome related. Obesity is also responsible for 2–8% of healthcare costs and 10–13% of deaths in different parts of Europe.
Middle East: The recorded high prevalence of the metabolic syndrome and its key cardiovascular risk factors (15-60%) among Middle East population mandates the need for a national and international prevention programs to combat obesity, diabetes, hypertension, smoking etc. A survey reported a prevalence of 33.9% for metabolic syndrome, with a higher prevalence in women (39.6%) than in men (28%) in Middle East region.
Asia Pacific: It is the leading cause of death in most countries, with ~366 million diabetics and metabolic syndromes in 2011 and an estimated 552 million in 2030. Asia have the greatest numbers of people with diabetes, and by 2025, they could each have 20 million affected individuals. The global diabetes drug and devices market is estimated to be a whopping 72.4 billion by 2018
London’s Medical sector is a shining jewel and a cornerstone of the city’s economy. With a rich history of achievements and medical firsts, the sector employs more than 20,000 in private sector industry, hospitals and research facilities including more than 2,000 researchers. The sector impact is in the manner: $720 Million Indirect benefits/ Economic Spinoffs; 780 number of principal researchers and 19 research institutes. The Major Biotech Companies in London are: Albert Browne Ltd, Parexel Informatics, Alcon Laboratories (UK) Ltd, Baxter Healthcare Ltd, Galderma Laboratories, Agilent Technologies, Abbott Laboratories, and Bayer Healthcare.
Also there are so many and so many researchers who are doing research on Metabolic Syndrome, Diabetes, Obesity, Cardiovascular disease and their related areas.
London is the capital and most populous city of England, United Kingdom and the European Union. With an estimated 2015 population of 8.63 million within a land area of 1,572 km², London is a leading global city, with strengths in the research and development, arts, commerce, education, entertainment, fashion, finance, healthcare, media, professional services, tourism, and transport all contributing to its prominence. It is one of the world's leading financial centres and has the fifth-or sixth-largest metropolitan area GDP in the world depending on measurement.
London is a world cultural capital. It is the world's most-visited city as measured by international arrivals and has the world's largest city airport system measured by passenger traffic. London's 43 universities form the largest concentration of higher education institutes in Europe.
Metabolic syndrome is a clustering of abnormalities characterized by the association of insulin resistance/type 2 diabetes, hyperlipidaemia, hypertension, and abdominal obesity. Advances in scientific research, the increasing prevalence of obesity, and the disorder's role in contributing to cardiovascular disease and diabetes are fuelling interest in metabolic syndrome. The most important risk factors are diet, genetics, stress, aging, sedentary behaviour or low physical activity, disrupted chronobiology/sleep, mood disorders/psychotropic medication use, and excessive alcohol use.
Recently, the Consensus Panel International Diabetes Federation (IDF) proposed a new definition for the Metabolic Syndrome that emphasizes the importance of central obesity. The European Global Cardiometabolic Risk Profile in Patients with Hypertension Disease survey investigated the cardiometabolic risk profile in adult patients with hypertension across 289 locations in four European regions. A study assessing data collected between 1997 and 2003 reported that the prevalence of obesity, defined as body mass index, varied between 6% and 20%, with higher prevalence in Central and Eastern European countries and lower values in France, Italy and some Scandinavian countries. With the exception of the Italian, Norwegian and UK cohorts, the prevalence of obesity was much higher in the European populations that were reported in the most recent review addressing the distribution of obesity in Europe. National U.S. survey data suggest the Metabolic Syndrome affects about one-quarter of adults aged 20 to 70 years, with the prevalence approaching 50% in the elderly.
Conference Series LLC organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members